目标TLR4抑制剂的设计,合成和抗风湿性关节炎活性
Wenbin Wang1, Shiyang Zhou2, Wenming Jiang1
1Chongqing Chemical Industry Vocational College, Chongqing 401228, China; Chongqing (Changshou) Green Chemical and Material Industry Technology Research Institute, Chongqing 401228, China.
Bioorganic & medicinal chemistry
|December 9, 2023
概括
针对托尔类受体4 (TLR4) 的新药候选药物在类风湿关节炎治疗中表现有前途. 化合物3p在临床前模型中有效抑制细胞增殖和关键炎症标志物,表现优于甲状腺素.
科学领域:
- 药用化学 医学化学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,其特征是关节炎症.
- 收费类受体4 (TLR4) 信号传递与RA的病变发生有关.
- 现有的治疗方法有局限性,需要开发新的治疗药物.
研究的目的:
- 设计和合成新型的1-(2-oxocyclohexyl) -butane-1,3-dione衍生物作为潜在的TLR4抑制剂.
- 评估这些化合物的体外和体外疗效,在类风湿性关节炎的临床前模型中.
- 为了研究最强效的化合物的作用机制.
主要方法:
- 合成的1-(2-oxocyclohexyl) 布-1,3-衍生物.
- 在体外测定:抑制大鼠突细胞增殖,LPS诱导的RAW264.7细胞增殖和TLR4活性.
- 在体内研究:对抗类风湿性关节炎效应的评估和炎症标志物 (TNF-α,IL-1β,IL-6) 的分析.
- 机制研究:对TLR4,JAK2和STAT3蛋白质和基因表达的评估.
主要成果:
- 化合物3p显著抑制了突细胞增殖 (IC50 = 1.21 μM) 和LPS诱导的RAW264.7细胞增殖 (IC50 = 0.73 μM).
- 化合物3p强烈抑制了TLR4活性 (IC50 = 0.43μM),表现优于阳性对照甲醇.
- 在体内,3p化合物有效抑制了关键的炎症性细胞因子 (TNF-α,IL-1β,IL-6) 并调节了TLR4/JAK2/STAT3信号通路.
结论:
- 合成的1-(2-oxocyclohexyl) butane-1,3-dione衍生物,特别是化合物3p,是强大的TLR4抑制剂.
- 化合物3p在类风湿性关节炎的临床前模型中表现出显著的抗炎和治疗作用.
- 这些发现表明,3p化合物是作为一种新的类风湿性关节炎治疗方法进一步开发的有希望的候选物.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
142
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
142
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Structure-Activity Relationships and Drug Design
728
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
728
Inflammatory Bowel Disease IV: Pharmacological Management
129
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
129
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168


